Lipocine: A Micro-Cap Stock That Can Compete In The NASH/NAFLD Race

|
About: Lipocine Inc. (LPCN)
by: Bridger Research
This article is exclusive for subscribers.
Bridger Research
Value, Growth, contrarian, long/short equity
Summary

The company reported top line interim 8-week Phase I clinical results of LPCN 1144 showing liver fat reductions compared to placebo.

Testosterone treatment can be a game changer in making the first cure on the market for NAFLD.

LPCN 1144's market opportunity is not fully priced in the current stock price.

Phase I LPCN 1144 Clinical Study

Lipocine (LPCN) reported the 8-week top line interim result from Liver Fat Study using magnetic resonance imaging, proton density fat fraction (“MRI-PDFF”) technique on January 17, 2019.